Prostate-specific antigen (PSA) has long been used to screen for prostate cancer (PCa), yet its low diagnostic sensitivity in the so-called PSA “gray zone” often results in overdiagnosis or missed diagnoses. Here, KLK3 is linked to prostate carcinoma.